Tag: LimFLow
LimFlow System a ‘cost-effective and high-value alternative’ to traditional therapies
Percutaneous Deep Vein Arterialisation (pDVA) with the LimFlow System offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent...
One-year outcomes from PROMISE I US study of LimFlow system published
LimFlow SA recently announced the publication of 12-month data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...
LimFlow receives Japan PMDA approval for clinical study of minimally-invasive technology
LimFlow announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification (CTN) for the Japanese cohort of...
PROMISE I: LimFlow system enables vast majority of patients to avoid...
LimFlow SA has announced the presentation of one-year data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...
Deep vein arterialisation should be considered in “no option” CLTI patients,...
Midterm results from a study of the largest population of patients with no-option chronic limb-threatening ischaemia (CLTI) treated with percutaneous deep vein arterialisation (pDVA)...
Positive two-year data from ALPS registry of LimFlow system published
LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialisation (pDVA) system. Results were...
VIVA 2019: LimFlow announces positive six-month data From PROMISE I US...
LimFlow SA today announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the...
LimFlow completes enrolment in US feasibility study
LimFlow has announced completion of enrolment of the original 10-patient cohort in the US feasibility study of the LimFlow percutaneous deep vein arterialisation system....